Prognosis and molecular characteristics of IBD-associated colorectal cancer: Experience from a French tertiary-care center.

Autor: Hammoudi N; Université de Paris, INSERM U1160, EMiLy, Institut de Recherche Saint-Louis, Paris, France; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Lehmann-Che J; Department of molecular oncology, Hôpital Saint-Louis, Université Paris Cité, Paris, France., Lambert J; Department of biostatistics, Hôpital Saint-Louis, APHP, Paris University, Paris, France. Hôpital Saint-Louis, Paris - France., Amoyel M; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Maggiori L; Department of digestive surgery, Hôpital Saint-Louis, APHP, Université Paris Cité, Paris, France., Salfati D; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Tran Minh ML; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Baudry C; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Asesio N; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Poirot B; Department of molecular oncology, Hôpital Saint-Louis, Université Paris Cité, Paris, France., Lourenco N; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Corte H; Department of digestive surgery, Hôpital Saint-Louis, APHP, Université Paris Cité, Paris, France., Allez M; Université de Paris, INSERM U1160, EMiLy, Institut de Recherche Saint-Louis, Paris, France; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Aparicio T; Université de Paris, INSERM U1160, EMiLy, Institut de Recherche Saint-Louis, Paris, France; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France., Gornet JM; Gastroenterology Department, AP-HP, Hôpital Saint-Louis / Lariboisière, Paris, France. Electronic address: jean-marc.gornet@aphp.fr.
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2023 Sep; Vol. 55 (9), pp. 1280-1287. Date of Electronic Publication: 2023 Mar 04.
DOI: 10.1016/j.dld.2023.02.011
Abstrakt: Background: Little is known about the prognosis of colorectal cancer associated with inflammatory bowel disease (CRC-IBD) in a real-world cohort in France.
Methods: We conducted a retrospective observational study including all patients presenting CRC-IBD in a French tertiary center.
Results: Among 6510 patients, the rate of CRC was 0.8% with a median delay of 19.5 years after IBD diagnosis (median age 46 years, ulcerative colitis 59%, initially localized tumor 69%). There was a previous exposure to immunosuppressants (IS) in 57% and anti-TNF in 29% of the cases. A RAS mutation was observed in only 13% of metastatic patients. OS of the whole cohort was 45 months. OS and PFS of synchronous metastatic patients was 20.4 months and 8.5 months respectively. Among the patients with localized tumor those previously exposed to IS had a better PFS (39 months vs 23 months; p = 0.05) and OS (74 vs 44 months; p = 0.03). The IBD relapse rate was 4%. No unexpected chemotherapy side-effect was observed CONCLUSIONS: OS of CRC-IBD is poor in metastatic patients although IBD is not associated with under-exposure or increased toxicity to chemotherapy. Previous IS exposure may be associated with a better prognosis.
Competing Interests: Conflict of interest MA received grant supports from Innate Pharma, Janssen, Takeda, Genentech/Roche, and honoraria for teaching activities or consultancy from Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Genentech, Gilead, IQVIA, Janssen, Novartis, Pfizer, Roche, Takeda, Tillots. T.A. presented conferences for Shire, Ipsen, Amgen, BMS, Servier, Pfizer, Roche Sanofi and meeting grants for Ipsen, Novartis, Roche and Hospira. He also obtained research grant from Novartis and Innate Pharma. N.H. received honoraria for consultancy from Janssen and Takeda. M.L.T.M. received honoraria from Abbvie and Janssen. J.M.G. has been a speaker and/advisory board member for Abbvie, Amgen, Celltrion, Takeda, Janssen and Sanofi Genzyme. N.L. has been a speaker for Sanofi. J.L.C., J.L., M.A., L.M., C.B., N.A., B.P., and H.C. have no conflict of interest to declare.
(Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: